An Ovarian Cancer Companion PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download An Ovarian Cancer Companion PDF full book. Access full book title An Ovarian Cancer Companion by Diane Sims. Download full books in PDF and EPUB format.
Author: Diane Sims
Publisher: GeneralStore PublishingHouse
ISBN: 9781894263832
Category : Medical
Languages : en
Pages : 160
Get Book Here
Book Description
"Ovarian cancer: its mere mention is shrouded in fear and mystery.... Draped in a cloak of anonymity, ovarian cancer is often called `the disease that whispers.' Diane Sims Roth, herself an ovarian cancer survivor, joins almost one hundred women with their personal anecdotes of their experience with ovarian cancer. Invaluable information is included: symptoms, treatment and prognosis, descriptions of risk factors, diagnostic procedures, drug therapies, radiology, and surgical procedures."
Author: Diane Sims
Publisher: GeneralStore PublishingHouse
ISBN: 9781894263832
Category : Medical
Languages : en
Pages : 160
Get Book Here
Book Description
"Ovarian cancer: its mere mention is shrouded in fear and mystery.... Draped in a cloak of anonymity, ovarian cancer is often called `the disease that whispers.' Diane Sims Roth, herself an ovarian cancer survivor, joins almost one hundred women with their personal anecdotes of their experience with ovarian cancer. Invaluable information is included: symptoms, treatment and prognosis, descriptions of risk factors, diagnostic procedures, drug therapies, radiology, and surgical procedures."
Author: Joi L. Morris
Publisher: Prometheus Books
ISBN: 1615927735
Category : Health & Fitness
Languages : en
Pages : 397
Get Book Here
Book Description
This unique and important guidebook is a single, comprehensive source of information and advice to help women (and some men) at high risk for breast and for ovarian cancer because of family history and genetic profile. One part memoir, three parts "how to" manual, Positive Results explains in a clear and steady manner the myths and realities of "the breast cancer genes." It lays out all the options in easy-to-follow, compassionate language. It will help women and men decide if they want to pursue genetic testing, guide them in interpreting their test results, and give them a sound basis for making the life-saving decisions required to manage their risks. Authors Joi Morris and Dr. Ora Karp Gordon cover all of the latest medical options, including genetic testing for breast cancer risk, breast cancer surveillance, assessing risk, mastectomy and breast reconstruction techniques, ovarian cancer surveillance, surgery, managing menopause, and cancer risks in men who carry mutations on BRCA genes. Along the way, Joi tells her personal story and that of other women and men who have made the gut-wrenching decisions required to survive in this world of astronomical risk. At the age of forty-two, Joi learned that she has a genetic mutation on a gene known as BRCA2. The test results meant that her risk of getting breast cancer could be as high as 84 percent by age seventy, and that her risk for ovarian cancer was also high. Compounding her risk was the fact that her mother had developed breast cancer in her forties. After much research and consultation, the result of which is this book, Joi made the difficult decision of undergoing prophylactic mastectomies. This straightforward and practical approach combined with the poignant personal experience of a woman at risk facing these challenging decisions will provide readers with the feeling that they have had the benefit of a long conversation with both a trusted physician and a friend who has just gone through the same uncertainties they are facing.
Author: Jan Trøst Jørgensen
Publisher: Academic Press
ISBN: 0128135409
Category : Medical
Languages : en
Pages : 509
Get Book Here
Book Description
Companion and Complementary Diagnostics: From Biomarker Discovery to Clinical Implementation provides readers with in-depth insights into the individual steps in the development of companion diagnostic assays, from the early biomarker discovery phase straight through to final regulatory approval. Further, the clinical implementation of companion diagnostic testing in the clinic is also discussed. As the development of predictive or selective biomarker assays linked to specific drugs is substantially increasing, this book offers comprehensive information on this quickly-evolving area of biomedicine. It is an essential resource for those in academic institutions, hospitals and pharma, and biotech and diagnostic commercial companies. - Covers all aspects, from biomarker discovery, to development and regulatory approval - Explains the "how to" aspects of companion diagnostics - Incorporates information on the entire process, allowing for easier and deeper understanding of the topic
Author: Robert E. Bristow
Publisher: CRC Press
ISBN: 0429578857
Category : Medical
Languages : en
Pages : 681
Get Book Here
Book Description
Updated and expanded, the third edition of Surgery for Ovarian Cancer focuses on essential techniques for the effective management of ovarian cancer. It reflects the most contemporary science and surgical applications for the management of patients with ovarian cancer and related peritoneal surface malignancies. This new edition takes a step-by-step approach and includes new intraoperative photographs and videos illustrating surgical procedures. It is principally devoted to the technical aspects of cytoreductive surgery, with chapters divided according to anatomic region. The chapters cover relevant anatomical considerations, surgical challenges specific to each region, and operative approaches and techniques favored by the authors. The list of contributing authors has been expanded from the previous edition and includes international and world-renowned experts from the fields of gynecologic oncology and surgical oncology. The topics of minimally invasive surgery, secondary cytoreduction, palliative surgery, and postoperative care are also covered in detail. New to the third edition are chapters on preoperative risk stratification, regional therapeutics and peritonectomy procedures, and quality assurance relating to ovarian cancer surgery. This comprehensive text is essential reading for all practitioners working with patients with ovarian cancers.
Author: Joerg Herrmann
Publisher: Elsevier Health Sciences
ISBN: 0323681360
Category : Medical
Languages : en
Pages : 547
Get Book Here
Book Description
Today's patients have unique cardiologic needs before, during, and after cancer treatment. Chemotherapies, radiation therapy, and targeted therapies can produce acute side effects or lasting adverse consequences on the heart and circulatory system, making the field of cardio-oncology increasingly important in effective patient care. Cardio-Oncology Practice Manual is a comprehensive, portable guide that provides practical approaches to assessment and management of cardiovascular diseases due to the effects of cardiotoxic agents and treatments. Part of the Braunwald family of renowned cardiology references, it clearly presents clinically relevant aspects of this growing field in one quick, practical reference for a wide range of cardio-oncology providers. - Covers all major cancer therapies, cardiovascular toxicities, and malignancies in a portable, authoritative guide—ideal for cardiologists, cardio-oncologists, general practitioners, internists, medical oncologists, and hematologists. - Offers templated and streamlined content for quick retrieval, with key point summaries for each major section. - Presents cardiac disease entities and specific malignant diseases in a succinct overview format addressing important clinical care aspects. - Features "Central Illustrations" for each topic that visually summarize the chapter and its specific content including algorithms for management of cardiovascular toxicities and one-view overviews of malignancies. - Includes a comprehensive drug guide that provides quick reference to drugs prescribed for cancers with therapeutic indications, manifestations and mechanisms of cardiotoxicity, their risk factors, and risk reduction strategies. - Brings you up to date with new immune therapies, including immune checkpoint inhibitors and CAR T-cell therapies
Author: Vivek M. Rangnekar
Publisher: Springer Nature
ISBN: 3030805581
Category : Medical
Languages : en
Pages : 329
Get Book Here
Book Description
Par-4 is a naturally occurring tumor suppressor. Studies have indicated that overexpression of Par-4 selectively induces apoptosis in cancer cells while leaving normal, health, cells unaffected. Mechanisms contributing to this cancer-selective action of Par-4 have been associated with PKA activation of intracellular Par-4 in cancer cells or GRP78 expression primarily on the surface of cancer cells. On the other hand, endogenous Par-4 sensitizes cells to the action of a broad range of apoptotic inducers acting via the extrinsic and intrinsic pathways. A number of binding partners of Par-4 have been identified and shown to regulate Par-4 function in cancer and other diseases, such as Alzheimer’s and major depression. Recent studies have recognized a number of natural products, dietary supplements, synthetic molecules and FDA-approved drugs that induce the secretion of Par-4 protein to cause apoptosis in primary or metastatic tumors, one of which is in clinical trials. More than 50 different laboratories worldwide are involved in Par-4 based research of this unique protein that has progressed from the bench to clinical trials. This second, companion volume will provide a comprehensive overview of Par-4’s role in cancer and other diseases. Chapters are written by leading researchers, and will be useful for a broad audience across the scientific community, particularly students and trainees, who are the next generation of scientists and clinicians to participate in new studies and discoveries on Par-4.
Author: Omer Devaja
Publisher: BoD – Books on Demand
ISBN: 1789843332
Category : Medical
Languages : en
Pages : 366
Get Book Here
Book Description
Ovarian cancer management is a rapidly changing field with new treatment agents available as a result of a greater understanding of the pathogenesis of this disease. In addition, both surgical and chemotherapeutic treatment strategies are evolving to maximise response in this disease. This book brings together leading specialists from around the world to discuss and outline a variety of new concepts in ovarian cancer, ranging from molecular biology and genetics through screening to both surgical and chemotherapeutic management.
Author: Robert J. Kurman
Publisher: World Health Organization
ISBN: 9789283224358
Category : Medical
Languages : en
Pages : 307
Get Book Here
Book Description
WHO Classification of Tumours of Female Reproductive Organs is the sixth volume in the 4th Edition of the WHO series on histological and genetic typing of human tumours. This authoritative, concise reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome. Diagnostic criteria, pathological features, and associated genetic alterations are described in a strictly disease-oriented manner. Sections on all recognized neoplasms and their variants include new ICD-O codes, epidemiology, clinical features, macroscopy, pathology, genetics, and prognosis and predictive factors. The book, prepared by 91 authors from 19 countries, contains more than 400 colour images and tables, and more than 2100 references
Author: Seigo Nakamura
Publisher: Springer Nature
ISBN: 9811645213
Category : Medical
Languages : en
Pages : 324
Get Book Here
Book Description
This highly informative and clearly written book presents the basic science and the latest data on hereditary breast and ovarian cancer (HBOC) to provide an up-to-date and holistic overview of the disease. It starts off by presenting the molecular mechanisms, genetic testing and counseling, and variants of unknown significance (VUS) to help readers understand the contemporary interpretation of the disease. Further chapters focus on the surveillance, diagnosis and treatment, including chemoprevention, risk reduction and drug development based on molecular mechanisms. It also includes a chapter on the latest findings from the HBOC database, ethical issues and the parp inhibitors, and discusses innovative thinking to manage and understand the disease. Hereditary Breast and Ovarian Cancer - Molecular Mechanism and Clinical Practice offers breast surgeons, medical oncologists, gynecological oncologists and genetic counselors a comprehensive overview of the disease. Providing insights into recent scientific findings and further avenues for investigation, it is also a thought-provoking and informative read for researchers and scholars.
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309380499
Category : Medical
Languages : en
Pages : 397
Get Book Here
Book Description
In an era of promising advances in cancer research, there are considerable and even alarming gaps in the fundamental knowledge and understanding of ovarian cancer. Researchers now know that ovarian cancer is not a single disease-several distinct subtypes exist with different origins, risk factors, genetic mutations, biological behaviors, and prognoses. However, persistent questions have impeded progress toward improving the prevention, early detection, treatment, and management of ovarian cancers. Failure to significantly improve morbidity and mortality during the past several decades is likely due to several factors, including the lack of research being performed by specific disease subtype, lack of definitive knowledge of the cell of origin and disease progression, and incomplete understanding of genetic and non-genetic risk factors. Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines avenues for translation and dissemination of new findings and communication of new information to patients and others. This study makes recommendations for public- and private-sector efforts that could facilitate progress in reducing the incidence of morbidity and mortality from ovarian cancers.
